DSS

| CancerCode	pvalue	Hazard Ratio(95%CI)
GBMLGG(N=598)	3.0e-14	1.73(1.50,1.99)
LGG(N=466)	2.5e-6	1.60(1.31,1.95)
UVM(N=74)	0.03	1.96(1.05,3.67)
THYM(N=117)	0.04	2.93(1.03,8.29)
TGCT(N=128)	0.04	4.77(0.97,23.57)
KIRC(N=504)	0.07	1.21(0.98,1.50)
LUSC(N=418)	0.07	1.17(0.99,1.39)
UCEC(N=164)	0.12	1.29(0.94,1.77)
KIPAN(N=840)	0.13	1.12(0.97,1.30)
COADREAD(N=347)	0.14	1.20(0.94,1.54)
COAD(N=263)	0.15	1.20(0.94,1.55)
GBM(N=131)	0.16	1.17(0.94,1.47)
LIHC(N=333)	0.27	1.13(0.91,1.42)
BLCA(N=385)	0.29	1.08(0.94,1.24)
KICH(N=64)	0.46	1.35(0.61,2.97)
UCS(N=53)	0.49	1.13(0.80,1.58)
PAAD(N=166)	0.59	1.05(0.87,1.27)
DLBC(N=44)	0.59	1.26(0.55,2.87)
STAD(N=351)	0.62	1.05(0.87,1.26)
ESCA(N=173)	0.71	1.05(0.82,1.35)
STES(N=524)	0.80	1.02(0.88,1.18)
READ(N=84)	0.91	1.05(0.46,2.42)
SKCM(N=438)	2.8e-3	0.82(0.71,0.93)
SKCM-M(N=341)	0.01	0.84(0.73,0.96)
BRCA(N=1025)	0.02	0.80(0.67,0.96)
KIRP(N=272)	0.02	0.67(0.48,0.94)
SARC(N=248)	0.06	0.84(0.70,1.01)
SKCM-P(N=97)	0.10	0.56(0.28,1.12)
LUAD(N=457)	0.20	0.92(0.81,1.05)
CESC(N=269)	0.41	0.88(0.66,1.18)
OV(N=378)	0.45	0.96(0.86,1.07)
HNSC(N=485)	0.50	0.94(0.78,1.13)
CHOL(N=32)	0.52	0.82(0.45,1.49)
PRAD(N=490)	0.61	0.67(0.15,3.03)
MESO(N=64)	0.72	0.95(0.70,1.28)
ACC(N=75)	0.81	0.94(0.59,1.51)
THCA(N=495)	0.97	0.98(0.28,3.43)
PCPG(N=170)	0.99	0.99(0.29,3.38)

log2(Hazard Ratio(95%CI))

Supplementary Fig. 1. Expression of CSF3R is associated with poorer overall survival (OS) in tumor patients

Supplementary Fig. 2. Association of CSF3R with immune regulation and immune treatment in glioma